HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection. Scandinavian Isoprinosine Study Group.

Abstract
The safety and clinical impact of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported. Of 866 HIV-seropositive patients randomized, 832 subjects were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS and/or death. Within 48 weeks, 10/412 (2.4%) patients assigned isoprinosine and 27/420 (6.4%) patients assigned placebo progressed to AIDS (P = 0.005). Intention-to-treat analysis showed identical results. Viewing the open treatment phase in isolation revealed no difference in progression rates between those treated and those not receiving the drug, perhaps reflecting the higher proportion of patients receiving zidovudine or PCP prophylaxis in the latter group. No severe adverse reactions or toxicities were observed. We conclude that HIV-seropositive patients without AIDS may be safely and effectively treated with isoprinosine.
AuthorsS Thorsen, C Pedersen, E Sandström, C S Petersen, G Norkrans, J Gerstoft, A Karlsson, K C Christensen, C Håkansson, P O Pehrson
JournalJournal of internal medicine (J Intern Med) Vol. 231 Issue 6 Pg. 607-15 (Jun 1992) ISSN: 0954-6820 [Print] England
PMID1377741 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Zidovudine
  • Inosine Pranobex
Topics
  • Acquired Immunodeficiency Syndrome (drug therapy, epidemiology)
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • HIV Seropositivity (drug therapy)
  • Humans
  • Inosine Pranobex (therapeutic use)
  • Male
  • Scandinavian and Nordic Countries (epidemiology)
  • Survival Analysis
  • Time Factors
  • Zidovudine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: